Through Blackhawk’s agreement with Emergence Technology Pty Ltd., the Company has the rights to distribute Innovita’s 2019-nCoV Ab test kit used in the detection of COVID-19 in Canada, the United States, Mexico, Germany, Switzerland and Austria.
The test kit is a small disposable point-of-care test (POCT) that can be used in clinics, hospitals, pathology labs, or in remote sites administered by health care professionals. The device itself is based on lateral flow colloidal gold-based detection technology that detects viral-specific IgG/IgM antibodies present in a few drops of blood from a finger prick. The device only requires 10 microlitres of patient serum or plasma, or 20 microlitres of whole blood, which is loaded on one end of the test kit, together with a buffer mix, which then mixes with COVID-19 spike proteins labelled with colloidal gold and migrates along the device to an area of immobilized antibodies that captures COVID-19 specific antibodies. If virus-specific IgG or IgM antibodies from the patient are present, compounds are formed, which show up as a distinctive purple band on the strip. The results are obtained within three to 15 minutes and do not require specialized laboratory equipment such as those that use real-time RT-PCR (reverse transcriptase-polymerase chain reaction) technology.
Innovita’s Covid-19 Rapid Test Kit
The test kit is developed and manufactured by Innovita (Tangshan) Biological Technology Co. Ltd. in China. Established in 2006 in Beijing, Innovita is a leading manufacturer of diagnostic solutions for respiratory pathogens diagnosis, striving for a more efficient health care system to enhance the health and well-being of everyone in the world. Innovita is currently in the process of manufacturing and distributing test kits in China. Readers are encouraged to visit their website for further information regarding Innovita.